Lixisenatide

What it is

Lixisenatide (Adlyxin in the US, Lyxumia outside US) is a synthetic 44-amino-acid GLP-1 receptor agonist derived from exendin-4 with structural modifications. It was developed by Sanofi, and the brand-name product Adlyxin was FDA-approved in 2016 for type 2 diabetes. The molecule is a once-daily injection administered before the morning or evening meal.

Lixisenatide differs from other GLP-1 agonists in having more pronounced effects on gastric emptying than on basal HbA1c — making it particularly effective for postprandial glucose control and somewhat less effective for fasting glucose. This pharmacological profile makes it useful in specific clinical scenarios but less suitable as a general weight management tool.

Mechanism of action

Standard GLP-1 receptor agonist mechanism with relatively pronounced effects on gastric emptying. Half-life of approximately 3 hours supports once-daily dosing patterns where the major effect is on the postprandial period following the dose.

Clinical use and evidence

Lixisenatide has been studied in the GetGoal trial program:

• HbA1c reductions of approximately 0.7–1.0% (smaller than other GLP-1 agonists)
• Weight loss of approximately 2 kg (smaller than other GLP-1 agonists)
• ELIXA cardiovascular outcomes trial: demonstrated cardiovascular safety in patients with recent acute coronary syndrome but did not show cardioprotective benefit

Lixisenatide is also available as a fixed-ratio combination with insulin glargine (Soliqua) for type 2 diabetes patients on insulin therapy.

Why we don’t prescribe it at The Tide

Lixisenatide is most often used for postprandial glucose control in type 2 diabetes and is typically managed by primary care or endocrinology.

The choice among GLP-1-based medications is made individually with a provider, based on each patient’s history, goals, and response.

Side effects and contraindications

Side effect profile parallels other GLP-1 agonists with somewhat more pronounced effects on gastric emptying that can lead to early satiety and increased GI symptom rates. Standard GLP-1 contraindications apply.